Chipscreen Biosciences, Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Chiauranib NCT06492915 |
P2 | Active, not recruiting | Pancreatic Ductal Adenocarcinoma | 42 | 2027-02-28 (+13 mo) |
| MECAP NCT07129382 |
P1/2 | Recruiting | Plaque Psoriasis | 220 | 2027-09-18 |
| Tucidinostat NCT06497985 |
P3 | Recruiting | Colorectal Cancer | 430 | 2028-05-31 |
| Chiauranib NCT07445295 |
P3 | Not yet recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 558 | 2028-06-30 |
| CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) NCT06947967 |
P3 | Recruiting | Lymphoma, T-Cell, Peripheral | 224 | 2032-12 (+12 mo) |